Background: Screening can detect prostate cancer at earlier, asymptomatic stages, when
treatments might be more effective. Purpose: To update the 2002 and 2008 US Preventive …

Background: In US men, prostate cancer is the most common noncutaneous cancer and the
second leading cause of cancer death. Screening for prostate cancer is controversial …

Background: Prostate cancer is the most common nonskin cancer in men in the United
States, and prostate cancer screening has increased in recent years. In 2002, the US …

Importance In the United States, the lifetime risk of being diagnosed with prostate cancer is
approximately 11%, and the lifetime risk of dying of prostate cancer is 2.5%. The median age …

Objective: To critically evaluate the evidence for recommending the screening of
asymptomatic men for prostate cancer with a blood test to detect a prostate-specific antigen …

Importance Prostate cancer screening with the prostate-specific antigen (PSA) test remains
controversial. Objective To review evidence from randomized trials and related modeling …

Recently, the US Preventive Services Task Force (USPSTF) published a review of the
evidence for screening for prostate cancer1 and made a clear recommendation against …

How often should we repeat either one? What is the patient's pretest probability of cancer?
What is the chance that a PSA test plus a biopsy will find cancer, if it's present? If cancer is …

Objectives The objective of this systematic review was to determine whether screening for
prostate cancer reduces prostate cancer mortality. Methods A systematic search for …

Key Clinical Points Prostate-Cancer Screening The introduction of prostate-specific antigen
(PSA) testing has nearly doubled the lifetime risk of receiving a diagnosis of prostate cancer …